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Tengis S. Pavlov 1, 2*, Vladislav Levchenko 1, Daria V. Ilatovskaya 1, Hui Li 3, Oleg Palygin 1,
Nuria M. Pastor-Soler 3, Kenneth R. Hallows 3 and Alexander Staruschenko 1
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA, 2Division of Hypertension and Vascular
Research, Henry Ford Hospital, Detroit, MI, USA, 3Division of Nephrology and Hypertension, Department of Medicine, Keck
School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA, USA
In the kidney, reabsorption via the epithelial sodium channel (ENaC) is involved
in long-term blood pressure control. Previously we demonstrated that ENaC hyperactivity
is associated with development of salt-sensitive (SS) hypertension in Dahl SS rats.
AMP-activated kinase (AMPK), playing a role in cellular energy homeostasis, has been
shown to decrease ENaC activity. Here, we tested whether metformin and AICAR, two
drugs that activate AMPK, affect the development of salt-induced hypertension. High salt
diet significantly increased mean arterial pressure (MAP) in Dahl SS rats. Blood pressure
elevation was accompanied by a short-term decline of heart rate and increased circadian
arterial pressure dipping. Metformin and AICAR were delivered intravenously at doses of
200 and 20 mg/kg/day, respectively. However, both control and drug-treated groups
had similar development of high blood pressure within 3 weeks of 8% NaCl dietary
salt intake. In the metformin-treated animals MAP reached 164.9 ± 9.1 mmHg, which
was not significantly different from the control group (171.8 ± 5.6 mmHg). Patch clamp
analysis revealed that the metformin-treated rats had no difference in the activity of ENaC.
AICAR treatment also did not affect the development of hypertension and kidney injury.
MAP reached 182.8± 4.8 and 178.0± 2.8 mmHg in AICAR and vehicle treated groups,
respectively. Of note, we found that high-salt diet activated AMPK in the Dahl SS rats,
and treatment with these AMPK activators had no significant further effect on AMPK
activity. We conclude that AMPK activators, at least under these conditions, do not affect
development of hypertension during high-salt diet in the Dahl SS rat model.
Keywords: hypertension, salt sensitivity, AMPK, metformin, AICAR, ENaC, blood pressure
INTRODUCTION
Activators of 5′-AMP-activated protein kinase (AMPK) are widely used for treatment of metabolic
disorders, type 2 diabetes, heart disease, anti-proliferative therapy and sports medicine. AMPK,
a heterotrimeric serine/threonine protein kinase, is activated in response to reduced intracellular
ATP to AMP ratio and controls numerous metabolic pathways. Activation of this kinase improves
glucose uptake, fatty acid oxidation and insulin sensitivity in skeletal muscles, carbohydrate and
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lipid metabolism in liver and adipocytes, and release of insulin by
pancreatic β cells (Long and Zierath, 2006).
A variety of medications work through AMPK and its
downstream pathways. For instance, the biguanide drug
metformin, in use since the 1950s, is a very effective agent for the
treatment of type 2 diabetes, insulin resistant states, pre-diabetes,
and cancer (Rojas and Gomes, 2013). Metformin acts primarily
in the liver by reducing glucose output and, secondarily, by
augmenting skeletal myocyte glucose uptake. Many mechanisms
are involved in the beneficial effects of metformin on cellular
metabolism; the activation of an upstream kinase, liver kinase B1
(LKB1), increased cellular AMP levels, and consequent AMPK
activation are considered to be key mechanisms for the action of
this drug (Zhou et al., 2001; Grahame Hardie, 2014).
Another example of AMPK axis targeting medications is
AICAR (5-amino-4-imidazole carboxamide ribonucleoside), an
AMP-mimetic and AMPK-regulating agent that is currently
being investigated for the treatment of metabolic syndrome
and as an ischemic preconditioning agent. Intravenous AICAR
administration reduces hepatic glucose output, inhibits whole
body lipolysis and lowers blood glucose concentrations in type
2 diabetic patients (Boon et al., 2008). Moreover, AICAR has
a prominent effect on skeletal muscles, enhancing glucose
uptake, training adaptation, and increasing endurance (Narkar
et al., 2008). Finally, pre- and peri-operative AICAR infusion in
patients undergoing coronary artery bypass graft surgery reduces
early cardiac death, myocardial infarction, and combined adverse
cardiovascular outcomes (Mangano, 1997).
Altered sodiummetabolism is a consistent finding in diabetes,
and it is present even in the absence of overt renal or cardiac
disease. Both insulin-dependent and non-insulin-dependent
diabetic individuals have been reported to have a significant
increase of total exchangeable sodium relative to non-diabetic
controls (O’hare et al., 1985; Bickel et al., 2002). In cultured
cells, AMPK was shown to regulate renal epithelial currents
mediated by ENaC (Bhalla et al., 2006), ROMK (Siraskar
et al., 2013), and CFTR (Takiar et al., 2011). Analysis of
renal function in mice with genetic deletion of the AMPK α1
catalytic subunit showed normal renal sodium handling and a
moderate antidiuretic state that might indicate a compensatory
upregulation in α2 subunit. A renal epithelium-specific knock
down of α2 subunit in the α1 knockout strain was accompanied
by reduced renal AMPK activity and a moderate salt/water
wasting phenotype on normal and high salt diets (Lazo-
Fernández et al., 2017).
The Dahl salt-sensitive rat strain is a well-established
model for studies of the NaCl-dependent type of hypertension.
This model recapitulates many traits of the human form of
salt-sensitive hypertension: suppressed plasma renin activity,
lower circulating aldosterone concentration, increased vascular
resistance, impaired pressure-natriuresis response, and decreased
venous compliance (Rapp, 1982; Rapp et al., 1989; Sullivan, 1991;
Cowley, 1997; Hall, 2016). A hallmark of Dahl SS rats is the
rapid progression of hypertension in response to high-NaCl diet.
Typical experimental protocols utilizing 4 or 8% NaCl chow
induce a substantial rise in blood pressure (BP) within 2–3 weeks
after the change of diet.
Sodium reabsorption via ENaC in the aldosterone-sensitive
distal nephron (ASDN) is one of the major factors that regulate
natriuresis and water-electrolyte balance in the organism. In
pathological conditions, increased ENaC activity is associated
with improper sodium handling, edema, excessive fluid
retention, and hypertension. For instance, hypertension is typical
for patients with Liddle’s syndrome caused by gain-of-function
mutations in ENaC (Hansson et al., 1995). We and others have
shown that in Dahl SS rats abnormal activation of ENaC on a
high salt diet contributes to the development of hypertension
(Kakizoe et al., 2009; Pavlov et al., 2013; Pavlov and Staruschenko,
2016).
It is currently unclear whether AMPK activators may
be beneficial in the treatment of salt-sensitive hypertension.
Experiments on airway tissue cultures reveal that ENaC-
dependent short-circuit currents are substantially inhibited by
AMPK activation (Woollhead et al., 2007; Myerburg et al., 2010).
Zhang and colleagues did not find any effects of metformin on
salt-induced hypertension in Dahl SS rats (Zhang et al., 1994).
However, in later studies intracerebroventricular administration
of metformin was found to prevent salt-induced blood pressure
increase in the spontaneously hypertensive rat (SHR) model
(Petersen et al., 2001). Recently, Yu et al. demonstrated that
chronic administration of caffeine augments AMPK activity in
Dahl SS rats and attenuates hypertension via a decrease of ENaC
activity in the ASDN and improved natriuresis (Yu et al., 2016).
In the current study, we used chronic intravenous metformin and
AICAR treatments to test how these AMPK activators affect the
development of SS hypertension and ENaC activity in Dahl SS
rats.
METHODS
Animals and Surgery
Experiments were performed on Rapp Dahl salt-sensitive (SS)
rats (SS/JrHsdMcwi) bred at the Medical College of Wisconsin.
Animal use and welfare procedures adhered to the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals following protocols reviewed and approved by the
Medical College of Wisconsin Institutional Animal Care and Use
Committee. At the age of 7.5 weeks the rats were anesthetized
with inhalation of 2.5% isoflurane in 0.5 l/min O2 flow. We used
two approaches to register blood pressure. To study effects of salt
intake (Figure 1), DSI telemeters (#TA11 PA-C40, Data Sciences
International, St. Paul, MN) were installed in femoral arteries
and affixed in a subcutaneous pocket in the loin area. Animals in
individual cages were placed on an RPC-1 Transceiver interfaced
via PhysioTel controller to computer equipped with the Ponemah
software package.
For the experiments with drug infusion (Figures 2–6),
catheters (#RPT080 Braintree, MA) were implanted in
the femoral artery and vein, tunneled subcutaneously, and
exteriorized at the back of the neck in a lightweight tethering
spring (Moreno et al., 2007; Pavlov et al., 2013). Following
recovery from anesthesia, all rats were placed into individual
stainless steel cages that permit daily measurement of arterial
blood pressure. The catheters were connected to pressure
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FIGURE 1 | AMPK activity is increased in salt-induced hypertension. (A) Mean arterial blood pressure in Dahl SS rats fed a 0.4% (n = 4), 4% (n = 3), or 8%
(n = 5) NaCl diet measured with DSI telemetry. Sodium (B) and potassium (C) urinary excretion (mM/mg of creatinine) before and after diet challenge (n = 5 in each
group). (D) Western blot of kidney cortex lysates isolated from the animals on 0.4 and 8% diets. Samples were tested for expression of phosphorylated acetyl-CoA
carboxylase (pACC) and AMPKα levels as indicators of AMPK pathway activity. (E) Summary graph of pThr172-AMPKα, p-ACC and AMPKα abundances, along with
β-actin as a loading control (*p < 0.05 vs. 0.4% NaCl for each parameter, unpaired t-tests, n = 3).
transducer (#041516504A, Argon Medical Devices, Plano, TX)
via swivels (#375/D/22 Instech, Plymouth Meeting, PA) for
arterial blood pressure acquisition and intravenous drug infusion
with the syringe pump (10 ml/day). The rats were allowed to
recover for at least 3 days following surgery.
Experimental Protocol
After the recovery period, blood pressure measurements were
obtained continuously for the duration of the experiment.
Plotted mean arterial pressure (MAP) data represent mean
measurements from 9:00 a.m. to 12:00 p.m. as described
previously (Pavlov et al., 2013). 20 mg/kg/day of AICAR
or 200 mg/kg/day metformin (Tocris, Minneapolis, MN)
administration was performed with continuous infusion at a rate
of 6.9 µL/min through the venous catheter in saline, which was
also used as a vehicle. After 3 days recovery when animals were
fed a normal 0.4%NaCl diet, rats were switched to a 4 or 8%NaCl
diet for 3 weeks (Dyets, Bethlehem, PA). Urine samples were
collected during infusion experiments and Na+, K+, protein, and
creatinine levels were analyzed as previously described (Pavlov
et al., 2016). Blood was collected during the experiment with
bleeds from the arterial catheters on conscious rats while resting,
and plasma glucose level was then measured with a Contour strip
glucometer (Bayer, Mishawaka, IN). At the end of the protocols,
the kidneys of rats were perfused (6 ml/min) through the distal
aorta with saline to clear them from blood, and then the renal
tissues were collected for further analyses (Pavlov et al., 2015a).
Western Blot
Kidney cortical lysates were prepared as follows. Renal cortexes
were excised rapidly and snap frozen in liquid nitrogen. Lysates
were prepared using a Dounce homogenizer in lysis buffer
[containing 20 mM Tris-HCl pH 7.4, 50 mM NaCl, 50 mM NaF,
5 mM Na-pyrophosphate, 250 mM sucrose, 1% Triton X-100, 1
mM DTT, 1 mM PMSF, and complete protease inhibitor cocktail
(Roche)]. Homogenates were centrifuged at 16,000 × g for 30
min at 4◦C, and the protein concentration in the supernatants
was measured using the Bradford technique (Bio-Rad protein
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FIGURE 2 | Metformin does not alter the development of SS hypertension. (A) Experimental protocol for BP recording. Continuous BP acquisition via catheters
was performed in conscious Dahl SS rats placed on an 8% NaCl diet and subjected to an intravenous infusion of metformin (n = 9) or vehicle (n = 6). (B)
Representative systolic (black) and diastolic (red) blood pressure recordings from a vehicle-treated animal. Data were averaged in 1 min intervals. (C) Mean arterial
blood pressure (MAP) in the vehicle- and metformin-treated groups. (D) Metformin does not affect MAP circadian dipping increase during development of
hypertension. (E) Representative heart rate trace acquired from a vehicle-treated animal. (F) Lack of effect of metformin on heart rate in experimental animals. *,#p <
0.05 vs. 0.4% NaCl; §,$p < 0.05 vs. 8 days on 8% NaCl.
FIGURE 3 | Metformin treatment reduces Glut2 expression in the liver. (A) Urinary sodium and potassium excretion and plasma glucose levels in vehicle- and
metformin-treated rats. (B) Immunohistochemical staining demonstrates that metformin treatment decreases abundance of hepatic Glut2, a key glucose transporter
involved in glucose release (40x). Scale bar = 50 µm. Shown on the right is summary graph for Glut2 relative abundance (**p < 0.01 relative to vehicle).
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FIGURE 4 | ENaC activity in cortical collecting ducts of vehicle- and
metformin-infused animals. (A) Representative current traces for ENaC
activity measured in cell attached patches from freshly isolated CCDs. Rats
were fed with 8% salt diet and treated with either vehicle (N = 3) or metformin
(N = 5). Holding potential was –40 mV. (B) Summary graph of observed ENaC
activity (NPo), open probability (Po) of individual channels and number of
channels (N) in the patches.
assay kit). Samples were separated by Nu-PAGE 4–12% gradient
gels and electrically transferred to a polyvinylidene difluoride
(PVDF) membrane (Bio-Rad). Membranes were cut horizontally
at about 50 and 100 kDa to make three sections for probing.
The top was probed for pACC. The middle was probed for
pThr172-AMPKα. The bottom was probed for β-actin. The
middle part was then stripped and reprobed for total AMPKα.
We had similar results when we probed for AMPK-alpha first
and then stripped and reprobed for pThr172-AMPKα (Li et al.,
2015; Al-Bataineh et al., 2016). The membranes were blocked
in 5% milk for 1 h and then incubated with primary antibodies
in 5% BSA overnight at 4◦C. After washes in TBS 0.05%
Tween 20, the membrane was incubated with either goat anti-
mouse or anti-rabbit secondary antibodies for 1 h at room
temperature. Immunoreactive proteins were detected by the
Versa-Doc imaging system (Bio-Rad). Quantification of Western
blot bands was performed by densitometry using Quantity One
software (Bio-Rad).
Antibodies
Antibodies directed against AMPK-α, AMPK-α-phospho-
Thr172, and ACC1-phospho-Ser79 (acetyl coenzyme A) were
all obtained from Cell Signaling Technology (#2532, 2531, and
3661, Danvers, MA) and applied in dilution 1:1,000 as previously
described (Li et al., 2015; Al-Bataineh et al., 2016). Anti-β-actin
antibody was obtained from Sigma (A1978, St. Louis, MO;
Pastor-Soler et al., 2015).
Histochemistry
Formalin-fixed kidney sections were cut at 4 µm slices,
dried and deparaffinized for subsequent streptavidin-biotin
immunohistochemistry. After deparaffinization, the slides were
treated with a citrate buffer (pH 6) for a total of 35min. The slides
were blocked with a peroxidase block (DAKO, Carpinteria, CA,
USA), Avidin Block (Vector Labs, Burlingame, CA, USA), Biotin
Block (Vector Labs), and serum-free Protein Block (DAKO). For
kidney damage analysis, the tissue was stained with Masson’s
trichrome. For Glut2 staining, liver sections were embedded
in one paraffin block for tissue microarrays and slices were
incubated 1:200 overnight with anti-Glut2 antibodies (#sc-
9117, Santa Crus Biotech, Dallas, TX). Secondary detection
was performed with Goat anti-Rabbit biotinylated IgG (Biocare,
Concord, CA, USA) followed by Streptavidin HRP (Biocare)
and visualized with Diaminobenzadine (DAB, DAKO). ImageJ
software was used to assess intensity of Glut2 staining in
hepatocytes. Average signal levels in 10 areas in each liver were
measured, and background (counterstained samples treated with
secondary antibodies) was subtracted.
Electrophysiology
Patch-clamp electrophysiology was used to assess ENaC activity
in isolated, split-open rat cortical collecting duct (CCD). CCDs
were isolated from Dahl SS rats as described previously (Pavlov
et al., 2013, 2015b). Kidneys were cut into thin slices (<1 mm)
then placed into ice-cold physiologic saline solution (pH 7.4).
Collecting ducts were mechanically isolated from these slices by
micro-dissection using forceps under a stereomicroscope. CCDs
were split open with sharpened micropipettes controlled with
micromanipulators to gain access to the apical membrane.
Single-channel data were acquired using Axopatch 200B
or 700B amplifiers (Molecular Devices, Sunnyvale, CA, USA)
interfaced via a Digidata 1440 to a PC running pClamp suite
software (Molecular Devices). When signals were acquired with
anAxopatch 200B amplifier, currents were filtered with an 8-pole,
low pass Bessel filter LPF-8 (Warner Inst., Hamden, CT) at 0.2
kHz. The pipette was pulled with a horizontal puller (Sutter P-
97; Sutter Inst., Novato, CA). The resistance of the pipette in the
corresponding bathmediumwas 7–12M. Typical bath solution
was (in mM): 150 NaCl, 1 CaCl2, 2 MgCl2, 10 HEPES (pH 7.4).
Pipette solution for the cell-attached configuration was (in mM):
140 LiCl, 2 MgCl2 and 10 HEPES (pH 7.4). Gap-free single
channel current data from gigaohm seals in principal cells were
acquired and subsequently analyzed with Clampfit 10.2 software
(Molecular Devices).NPo, the product of the number of channels
(N) and the open probability (Po), was used to measure the
channel activity within a patch. Single-channel unitary current
(i) was determined from the best-fit Gaussian distribution of
amplitude histograms. Channel activity was analyzed as NPo =
I/i, where I is mean total current in a patch and i is the unitary
current at this voltage. Where appropriate, Po was calculated by
normalizing NPo for the total number of estimated channels in
the patch.
Statistics
All summarized data are reported as mean ± SEM. Data were
compared using one-way ANOVA or Wilcoxon signed-rank
test in case of dependent values; P < 0.05 was considered
significant.
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FIGURE 5 | AICAR does not alter development of SS hypertension. (A) Blood pressure recordings collected from vehicle- or AICAR-treated Dahl SS rats during
development of hypertension on an 8% NaCl diet (n = 6 and 5, respectively). Effect of AICAR treatment on the blood glucose level (B), proteinuria (C), sodium (D), and
potassium (E) excretion in Dahl SS rats fed an 8% diet. No significant differences between vehicle and AICAR-treated rats were found on any of the parameters tested.
RESULTS
Salt-Induced Blood Pressure Elevation Is
Associated with AMPK Activation
Dahl SS rats are known to develop hypertension when fed
a high-salt diet (Rapp, 1982). First, we confirmed this effect
using the DSI telemetry to monitor blood pressure in the rats
fed 0.4, 4, or 8% NaCl diets between 8 and 11 weeks of age.
The experiment revealed that during the 3-week period the
0.4% diet does not alter blood pressure, whereas the 4% diet
raised MAP, and the 8% diet augmented the development of
hypertension (Figure 1A). High NaCl diets increased sodium
excretion proportionally to sodium content in the chow whereas
potassium excretion remained stable, suggesting that food intake
was similar on all diets (Figures 1B,C). While 4% diet represents
a widely used dietary challenge, 8% diet had more profound and
faster effects on blood pressure. Therefore, we used 8% in our
subsequent experiments. At the end of the experiments, kidney
samples were collected for the assessment of protein expression.
No significant differences in terminal total body weights were
found: average mass was 325.7 ± 9.7 (0.4% NaCl) vs. 308.5 ±
1.3 g (8% NaCl).
Western blot analysis in kidney cortex samples with antibodies
that probe both α1 and α2 AMPK forms (559 and 552 amino
acids length, respectively) detect four major immunoreactive
bands (Figure 1D). Earlier, it was shown in rat liver tissue
that the AMPKα signal might migrate as doublets. The authors
also demonstrated that inactivation of AMPKα resulted in a
shift in the migration of the upper band of the doublet to
that of the lower band indicating that the two bands represent
different phosphorylation states of the same enzyme and that
activation is accompanied by a shift to higher bands (Carling
et al., 1994). Our further investigations revealed similar forms
of AMPKα which degrade in the renal tissues of AMPKβ1
knockout mice (Christensen et al., 2016). In the current study,
high-salt diet causes increased activation of AMPK pathway in
the renal cortex. 8% NaCl diet significantly increased both total
AMPKα subunit abundance and phosphorylation of the Thr172
residue in the “activation loop” of AMPKα subunit (Stein et al.,
2000). Phosphorylation of acetyl-CoA carboxylase (ACC), an
immediate downstream effector and canonical target of AMPK,
was also increased suggesting that high salt intake or high BP
increases cortical AMPK activity (Figures 1D,E).
Metformin Treatment Does Not Affect
Development of Salt-Sensitive
Hypertension
We tested whether the AMPK activator metformin affects blood
pressure elevation in Dahl SS rats. After catheter implantation,
recovery period and an initial 3 day blood pressure acquisition
on a 0.4% NaCl diet, an 8% salt supplement along with vehicle
or metformin infusion were instituted for an additional 21 day
period (Figure 2A).
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FIGURE 6 | AICAR treatment does not affect renal damage and cortical
AMPK activity. (A) Kidney morphology. Trichrome staining revealed that
AICAR treatment did not preclude renal damage in SS hypertension. Scale bar
= 2 mm. (B) Abundance of total AMPKα, phosphorylated Thr172-AMPKα and
phosphorylated acetyl-CoA carboxylase (pACC), a canonical target of AMPK
were studied in the renal cortex collected from the infused animals. No
difference in AMPK activity was found between the groups.
This high-salt challenge induced development of hypertension
within the experimental period. Figure 2B shows a representative
increase of systolic (black) and diastolic (red) blood pressures in
a Dahl SS rat infused with vehicle. The BP elevated in two phases.
The first stage was characterized by a sharp increase occurring
over 1–8 days after the change of diet with an increase in MAP
by ∼21 mmHg. Then BP rose slowly by ∼8 mmHg over 8–14
days from the switch in diet. Finally, during the 3rd week after
switching to a high-salt diet there was a second acute phase when
MAP rapidly rose up to 171.8 ± 5.6 mmHg (Figure 2C, black
dots).
Development of hypertension was also accompanied with an
increasing circadian BP dipping response: the difference between
day/night MAP on a low-salt diet was 17.4± 2.1 mmHg whereas
on a high-salt diet this value rose to 27.2 ± 0.8 mmHg on day
8 and 43.6 ± 5.9 mmHg by the end of experiment (Figure 2D).
We also observed a temporary significant drop in heart rate after
switching the diet, which recovered by day 21 (Figures 2E,F).
Metformin treatment in the high-sodium treated animals had
no influence on the pattern of hemodynamic changes: neither
MAP, circadian dipping, nor heart rate differed between vehicle-
and metformin-treated groups (Figures 2C,D,F). During the
experiment, sodium and potassium urinary excretion, plasma
glucose level (Figure 3A) as well as total body weight at the end
of the experiment (303.8± 12.5 vs. 309.6± 13.8 g) did not differ
between the groups.
Metformin Decreases Abundance of Glut2
Transporter in the Liver
Metformin is well-known to modulate cellular metabolism in
different tissues. Glut2 is a glucose transporter that mediates
diffusive glucose transport through the plasma membrane in a
variety of tissues (Thorens, 2015). To confirm that the infusion
of metformin reached its targets and had functional effects, we
assessedGlut2 expression in liver tissue collected after vehicle and
metformin treatment. Immunohistochemistry assays revealed
that metformin dramatically decreased the abundance of Glut2 in
hepatocytes (Figure 3B). Therefore, 200 mg/kg/day intravenous
metformin infusion had functional consequences in this rat
model, altering Glut2 expression and presumably liver metabolic
function.
Lack of Effect of Metformin on ENaC
Activity
We recently demonstrated that high ENaC activity contributes
to the development of hypertension in Dahl SS rats (Pavlov
et al., 2013). We and others have shown that the AMPK
pathway regulates ENaC activity in cultured cells and in vivo
(Carattino et al., 2005; Almaça et al., 2009; Myerburg et al., 2010),
although it is unclear whether this mechanism is functional
in the Dahl SS rats. Therefore, here we studied whether the
AMPK activator metformin has an effect on the activity of
ENaC in the experiments described above in this important
animal model of hypertension. CCDs were manually isolated
immediately after organ collection, and patch-clamp analysis
was performed on split-open tubules to assess channel activity.
Figure 4A demonstrates representative ENaC current traces
recorded from the apical membrane of vehicle- and metformin-
treated Dahl SS rats. The analysis did not reveal any significant
differences in total ENaC activity (NPo), open probability
of individual channels (Po) or the number of channels (N)
observed in patches (Figure 4B). Therefore, in this rat model
of hypertension, metformin treatment does not decrease ENaC
activity.
AICAR Treatment Does Not Affect
Development of Salt-Sensitive
Hypertension
Considering the lack of effect of metformin on blood pressure
elevation in Dahl SS rats, we tested whether another AMPK-
activating pharmacological agent, AICAR, attenuates high blood
pressure. Similarly, we found that 20 mg/kg/day continuous
AICAR administration had no effect on the development
of hypertension (Figure 5A). Analysis of the plasma samples
collected via arterial catheters revealed that both vehicle- and
AICAR-infused animals were euglycemic during the experiment
(Figure 5B). By the end of the study, both groups demonstrated
significant proteinuria, and neither sodium, potassium, total
urine (73 ± 1.2 vs. 72.5 ± 8.4 ml/day) excretion, nor total body
weight (288.4 ± 14.7 vs. 306 ± 7.3 g) differed between the two
groups (Figures 5C–E). Histological analysis revealed massive
abundance of protein casts, indicating kidney damage in the
renal tissues in both groups (Figure 6A). The abundances of p-
ACC, pThr172-AMPKα and total AMPKα, markers of AMPK
pathway activity, in the cortex of AICAR-treated animals were
similar to those of the control group as tested byWestern blotting
(Figure 6B).
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DISCUSSION
AMPK activators have proven themselves to be useful drugs for
metabolic disorders, including those associated with high blood
pressure. Recently, Lazo-Fernández and colleagues determined
that systemic knockout of α1 combined with kidney epithelium-
specific deletion of α2 AMPK subunits led to a water and
salt wasting phenotype in mice. The authors also suggested
that activity of NKCC2, which serves as a substrate for
phosphorylation by AMPK, might be reduced with AMPK
targeting (Lazo-Fernández et al., 2017). Another example of the
effect of AMPK on the renal concentrating ability in normal
animals comes from experiments on kidney slices isolated from
Sprague Dawley rats where AICAR treatment decreased apical
membrane localization of AQP2, which could have a diluting
effect on urine (Al-Bataineh et al., 2016). The current study was
aimed at investigating the prospect of targeting AMPK for the
treatment of salt-sensitive hypertension. Earlier, it was shown
with a precise servo-control of body fluid volume that fluid
retention is required to trigger the rise of pressure in Dahl SS rats
(Greene et al., 1990).
Four and even 8% sodium chloride diets are commonly used;
for instance, it was demonstrated that Dahl SS rats on an 8%NaCl
diet had similar plasma sodium and protein levels compared to
those on a 0.3% salt diet (and salt-resistant Dahl R rats on 8%
diet), whereas their urine flow and sodium excretion rates were
significantly higher as measured in pressure-natriuretic response
studies (Roman and Kaldunski, 1991; Kakizoe et al., 2009). We
have also shown that Dahl SS rats maintain stable plasma sodium
and potassium levels when switched to 8% NaCl (Pavlov et al.,
2013). We conclude that the rats could tolerate even such a high
salt load as 8% NaCl chow when they have unlimited access to
fresh water.
In the current study, salt-induced hypertension developed
in two phases, early and late, which is typical for Dahl SS
rats (Moreno et al., 2011; Evans et al., 2015). We observed an
elevation in MAP and a progressive increase in day/night blood
pressure dipping in all animals fed a high-salt diet, consistent
with earlier findings (Mori et al., 2008; Cowley et al., 2016). In
hypertensive and normotensive humans, nocturnal dipping is
usually defined as a >10% decline in BP (Henskens et al., 2008)
and has an important diagnostic significance: it has been shown
that impaired BP dipping is associated with increased risk of
cardiovascular events and target organ damage (Ohkubo et al.,
2002; De La Sierra et al., 2009). In subjects from African descent,
sodium excretory renal function during daytime was found to be
a significant determinant of nocturnal BP and dipping (Bankir
et al., 2008), whereas salt-resistant normotensive individuals’ BP
was not blunted on standard and high-sodium diets (Brian et al.,
2017). Also, metabolic syndrome is recognized as a predictor of
non-dipping hypertension (Tartan et al., 2006), and we expected
that targeting AMPK activity might have an effect on circadian
dipping in Dahl SS rats. However, in the current study blood
pressure elevation was not accompanied by impaired dipping
in either vehicle- or drug-treated animals. High-salt diet also
substantially increased the activity of AMPK in the kidney cortex
as revealed by Western blotting. We further tested whether
treatment with the AMPK activators metformin and AICAR
(given via intravenous infusion) affects the development of
hypertension.
We showed that metformin infusion at a dose of 200
mg/kg/day reduced Glut2 abundance in hepatocytes, which
demonstrated effective delivery and the targeting of liver function
by the drug. Glut2 is a bidirectional glucose transporter present
in liver, kidney, intestine, and pancreas, which facilitates glucose
transit from the interstitium to the cell and vice versa. Studies
have shown that Glut2 is overexpressed under diabetic conditions
due to the increased glycolysis associated with the enhanced
glucose transport (Zhang et al., 2013). Over-expression of
Glut2 in hepatic tissue was found in high-fat and fructose-
induced type-2 diabetic animals. Anti-diabetic treatment reduced
Glut2 expression in high-fat and fructose-induced type-2 rats
(Narasimhan et al., 2015).
However, we found a lack of effect of metformin on
hypertension development, ENaC activity, and heart rate changes
in this animal model. Similarly, earlier studies by Zhang
and colleagues have shown that metformin did not affect
development of hypertension in Dahl SS rats fed a 3% NaCl
diet (Zhang et al., 1994). On the other hand, Yu et al. recently
reported that chronic treatment with caffeine, which activated
AMPK, increased natriuresis and precluded 8% NaCl salt-
induced hypertension. Also, these authors suggested that in cell
culture studies this effect of caffeine might be mediated by
downregulation of ENaC via AMPK activation, as the caffeine
effect was blocked by the putative AMPK inhibitor compound
C (Yu et al., 2016). However, these results should be interpreted
with caution because compound C is known to have significant
off-target effects on a number of other kinases and signaling
pathways (Bain et al., 2007). We studied the effect of chronic
metformin administration on ENaC activity in the freshly
isolated CCD segments of these high-sodium fed animals and
did not detect any significant difference in ENaC function as
compared to vehicle-treated animals. The lack of effect in our
experiments may well be due to our finding that AMPK was
already strongly activated following the institution of a high-
salt (8% NaCl) diet (Figure 1), a finding that is consistent with
earlier work in rats fed a high-salt diet (Fraser et al., 2005).
Similarly, no further AMPK activation by AICAR infusion, as
compared to vehicle, was found in our studies using Dahl SS rats
fed a high-salt diet (Figure 6). It is therefore conceivable that
any potential effect of AMPK activation on the hemodynamic
parameters we measured was already maximized even in vehicle-
treated animals during this exposure period. It would thus be
interesting to examine the potential role of AMPK modulation
in other hypertension models where AMPK may not be already
activated.
Our study and the investigation by Zhang et al. used
metformin at the following doses: 200 mg/kg/day intravenously
and a daily dose of 300–350mg/kg in drinking water, respectively.
Metformin is usually used in rats in the 100–300 mg/kg/day
range orally or intravenously (Santuré et al., 2000; Choi et al.,
2008). In patients with type-2 diabetes, the oral form of
metformin is usually given at total doses of 500–2,000mg
daily (Stumvoll et al., 1995; Basu et al., 2008; Takahara et al.,
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2012). Interestingly, Santuré and colleagues found that 3 weeks
of treatment with metformin improves the glucose disposal
in SHRs but has no blood pressure-lowering effect and no
influence on vascular responses to insulin. In another study, 25–
200 µg/day intracerebroventricular administration of metformin
to SHRs attenuated 8% NaCl diet-induced hypertension; 100–
200 mg/kg doses were highly neurotoxic as demonstrated by
a histological evaluation post-mortem (Petersen et al., 2001).
Together, these considerations and findings suggest that the
selection of experimental model, route of administration, and
dosage may all be critical for studying the effects of AMPK
activators on blood pressure.
The renal effects of AMPK activators have been characterized
in less detail than in such systems as skeletal and cardiac
muscle or gastrointestinal tract. In our study, we have not
observed effects of AICAR infusion on renal salt handling
during BP elevation, although high-salt intake itself activated the
AMPK pathway even without AICAR treatment, as discussed
above. Another factor that could contribute to the observed
lack of effect of the AMPK activators on BP might be that
the dose was insufficient to target the kidneys. However, 200
mg/kg/day metformin did induce hepatic effects, which suggests
the physiological efficacy of this infusion. AICAR is often
used at high doses: antidiabetic effects are exhibited at doses
of ∼1 g/kg/day intravenously in humans (Boon et al., 2008)
and rodents (Minokoshi et al., 2002). The safety and kinetics
study in healthy men demonstrated that AICAR is poorly
bioavailable (<5%) when administered orally in solution; after
intravenous injection the elimination phase half-time (t1/2β) was
1.4 h (Dixon et al., 1991). Our much lower intravenous dose
of 20 mg/kg/day administration of AICAR did not exert any
effects.
We conclude that the observed inability of metformin and
AICAR at moderate and low doses to modulate blood pressure
and renal salt handling in the Dahl SS rat challenged with a high
salt diet warns against direct translation of these drugs toward
the treatment of salt-sensitive hypertension. Further, studies are
required to define an experimental approach and appropriate
animal models for further testing the potential applicability of
AMPK activators to this pathological condition.
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